UCB

UCB to Sell Neurology and Allergy Business in China

Belgium-headquartered biopharmaceutical company UCB is to sell its mature neurology and allergy business in China to Singapore-based asset management group CBC and investor Mubadala, based in Abu Dhabi, for $680 million.

Artificial Intelligence for New Drug Design

Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.

UCB Buys Handl, Partners Lacerta

Belgian biopharma UCB has announced two moves that will boost its gene therapy capabilities.

UCB Acquires Engage Therapeutics

At the Crossroads of Technology and Information

Raising the Profile of Your Information Center

The Art of the Alliance

Pharma Majors Join Parkinson’s Initiative

Mallinckrodt Challenge Says FDA Overstepped Bounds

UCB to Sell Established Brands in India to Dr. Reddy’s

China to Launch Fresh Pharmaceutical Bribery Probe

China Investigates France's Sanofi for Alleged Bribery

Top Insulin Maker Novo Caught Up In China's Widening Drug Probes

Drug Makers Fear Short-Term Turmoil As China Probes Widen

Foreign Pharma Companies Could Be Probed In China

China Pharma Probe Widens, U.S. Citizen Detained

Court Stops EU Regulator Releasing Drug Company Data

UCB in 2012: New Core Medicines Drive Growth

Drugmakers, Academics Pool R&D in $265 Million EU Project

Portfolio Management